Shiva Malek

7PUBLICATIONS
55CO-AUTHORS
Molecular targetsCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 25, 2026
Biomarker Analysis from Patients with Metastatic PDAC Treated with TGFβ Antibody NIS793 plus Abraxane + Gemcitabine versus Abraxane + Gemcitabine Alone in a Phase II, Open-Label, Randomized Study.

|Jun 11, 2026
Dynamic transitioning between MAPK-driven and WNT-driven cell states drives intestinal cancer and shapes therapy response.

|Sep 21, 2021
RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy.

Kyung W Song, Kyle A Edgar, Emily J Hanan

|May 06, 2021
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma.

Ivana Yen, Frances Shanahan, Jeeyun Lee

|Apr 03, 2021
Emerging Trends in Cancer Drug Discovery-From Drugging the "Undruggable" to Overcoming Resistance.

Joachim Rudolph, Jeff Settleman, Shiva Malek

|Sep 24, 2020
Dimerization Induced by C-Terminal 14-3-3 Binding Is Sufficient for BRAF Kinase Activation.

Nicholas P D Liau, Avinashnarayan Venkatanarayan, John G Quinn

Pageof 2

Frequent Collaborators

2 joint publications

Nicholas P D Liau

2 joint publications

Jawahar Sudhamsu

2 joint publications

Amanda R Moore

1 joint publications

Avinashnarayan Venkatanarayan